Table 2.

Therapeutic SEs and inhibitors.

SE inhibitor	Molecular target	Function	Tumor type	Ref.
JQ1	BRD4	Reducing BRD4 occupancy and MED1 binding, Pol II stalling and elongation impairment	AML	74,79
IBET	CDKs	Regulating RNAPII initiation and elongation	Unascertained	81
THZ1	CDK7	Inhibiting phosphorylation of CTD of RNA Pol II and hindering promoter proximal pausing	Neuroblastoma	65
	MYCN	Repression of MYCN-dependent transcriptional amplification	Neuroblastoma	65

AML acute myeloid leukemia, BRD4 bromodomain-containing protein 4, CDK cyclin-dependent kinase, CTD carboxyl-terminal domain, Pol II polymerase II.